Cellectis S.A. filings document a foreign private issuer focused on clinical-stage gene-edited cell and gene therapies. Recent Form 6-K reports furnish press-release exhibits covering financial-results announcements, business updates, research presentations, and clinical program disclosures for the company's allogeneic CAR T and gene-editing platforms.
The filing record also reflects disclosure topics tied to Cellectis' Nasdaq and Euronext Growth listings, including its Form 20-F reporting status, pipeline updates for lasme-cel, eti-cel and cema-cel, license and collaboration references involving Servier, Allogene and AstraZeneca, and formal communications about strategy, research data and corporate developments.
Cellectis S.A. (CLLS) announced a strategic transformation to focus on becoming an in vivo gene editing company, centered on two lead programs, .HEAL-101 for severe hypertriglyceridemia and .HEAL-201 for severe hypercholesterolemia. Both are supported by promising preclinical proof-of-concept and are planned to enter Phase 1 investigator-initiated trials in China, with preliminary data expected in H2 2027 for .HEAL-101 and H1 2028 for .HEAL-201.
The company will exit internal development of its allogeneic CAR-T candidates lasme-cel and eti-cel, citing a materially changed competitive and clinical landscape, and will seek partners for these assets while continuing its existing cell therapy collaborations with AstraZeneca, Allogene, Servier and Iovance. Cellectis plans to realign its operating model, including organizational changes, with the goal of extending its cash runway into H2 2028, excluding any impact from potential partnering of lasme-cel and/or eti-cel.
Cellectis S.A. (CLLS), a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, announced it will host a conference call and webcast on September 14, 2026 to provide a business update. The company will hold an English-language call at 8:00 a.m. ET / 2:00 p.m. CET, followed by a French-language call at 9:00 a.m. ET / 3:00 p.m. CET. Both events will be accessible via webcast and telephone, with a replay available on the company’s website.
Cellectis develops allogeneic CAR T immunotherapies and other gene therapies using its in-house gene-editing and manufacturing platform, with headquarters in Paris and additional locations in New York and Raleigh, NC.
Cellectis S.A. (CLLS) filed an amended Form 6-K mainly to add iXBRL formatting, while reaffirming its unaudited results for the six months ended June 30, 2026. Revenue fell to $11.0 million from $27.4 million, largely due to lower activity under AstraZeneca collaboration research plans, while other income rose modestly from higher research tax credits.
Research and development expenses increased to $52.2 million and selling, general and administrative expenses to $11.3 million, driving an operating loss of $48.7 million versus $23.8 million a year earlier. A swing to a $9.2 million net financial gain from an $18.1 million loss, helped by fair value gains on EIB warrants and lower FX losses, narrowed the net loss slightly to $39.6 million ($0.39 per share). Cash and cash equivalents were $35.6 million and current financial assets (fixed-term deposits) $131.3 million, and the company states this liquidity should fund operations for at least 12 months on a going-concern basis.
Cellectis S.A. (CLLS), a clinical-stage gene-editing biotechnology company, reports that its management will participate in several upcoming healthcare investor conferences in the U.S. and Europe from September through November 2026. Events include conferences hosted by Wells Fargo, Baird, Barclays, Stifel and Jefferies in Boston, New York and London.
Cellectis’ team will be available for investor meetings at these events, coordinated either through conference organizers or the company’s Investor Relations. Any available webcasts of presentations will be posted in the events and webcasts section of Cellectis’ investor website.
Cellectis reported second-quarter and first-half 2026 results while advancing its allogeneic CAR‑T pipeline. Lasme‑cel in r/r B‑ALL received FDA RMAT designation based on Phase 1 BALLI‑01 data showing a 100% overall response rate (7/7) and 57% CR/CRi in the target Phase 2 population with a manageable safety profile; a pivotal Phase 2 interim analysis is expected in Q4 2026. Eti‑cel in r/r NHL showed an 88% ORR and 63% CR rate in an optimal dose cohort, with full Phase 1 data planned in Q4 2026.
For the six months ended June 30, 2026, revenues and other income were $14.5 million versus $30.2 million a year earlier, and net loss attributable to shareholders was $39.6 million (adjusted net loss $35.6 million). Cash, cash equivalents and fixed‑term deposits totaled $169 million as of June 30, 2026, which the company believes will fund operations into Q4 2027. R&D expenses rose to $52.2 million, and net financial result swung to a $9.2 million gain from an $18.1 million loss.
Cellectis S.A. reported unaudited results for the six months ended June 30, 2026. Revenues were $11.0 million, mainly from the AstraZeneca joint research collaboration, down from $27.4 million a year earlier, and total revenues and other income were $14.5 million.
Research and development expenses rose to $52.2 million and selling, general and administrative costs to $11.3 million, leading to an operating loss of $48.7 million. A net financial gain of $9.2 million, driven largely by fair value gains on European Investment Bank warrants and markedly lower foreign-exchange losses, partially offset operating losses.
The period’s net loss was $39.6 million, or $0.39 per basic and diluted share, compared with a $41.9 million loss in the prior-year period. At June 30, 2026, cash and cash equivalents were $35.6 million and fixed-term deposits classified as current financial assets were $131.1 million. The company states these resources are sufficient to fund operations for at least twelve months after board approval of these financial statements.
Cellectis S.A., a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, stated it will report second quarter 2026 financial results for the quarter ended June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.
The company indicated it will not host a conference call for these results and directed investors to its website and investor relations contacts for the press release and any questions. Cellectis uses an allogeneic approach to CAR T immunotherapies and is listed on Nasdaq and Euronext Growth.
Cellectis S.A. filed an amended Form 6-K to correct a clerical error in the previously reported voting results of its Combined General Meeting of Shareholders held on June 25, 2026. The vote tallies themselves were already accurate and remain unchanged.
The amendment clarifies that Resolution 30, a delegation of authority to increase share capital for members of a company savings plan, was in fact rejected, not carried. Shareholders voted 57,625,365 votes (85.19%) against and 10,014,708 votes (14.81%) for this resolution. All other resolutions, including approval of 2025 financial statements, multiple capital increase delegations, share buyback authority, and equity-based compensation authorizations, were correctly reported as carried.
Cellectis filed a Form 6-K to report the results of its shareholders general meeting held on June 25, 2026 in Paris. At this meeting, about 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted and resolution 30 was rejected, in line with the board of directors’ recommendations. Detailed voting results are available on the company’s website. Cellectis is a clinical-stage biotechnology company developing gene-edited, off-the-shelf CAR T-cell therapies and other gene therapies, with shares listed on Nasdaq and Euronext Growth.
Cellectis S.A. reported the results of its Combined General Meeting of Shareholders held on June 25, 2026. Shareholders approved the 2025 annual and consolidated financial statements, allocation of results, and review of regulated agreements, with around 99.9% of votes in favor on the core financial items.
The meeting renewed four directors, including Jean‑Pierre Garnier and Cécile Chartier, and authorized the Board to repurchase shares and cancel repurchased shares, each with more than 99% support. A broad set of capital increase delegations was approved, many with cancellation of preferential subscription rights for targeted investor categories, including an equity financing program on the U.S. market through an “at‑the‑market” facility.
Shareholders also approved authorizations for stock options and free share grants, as well as related caps, and amended bylaws to reflect new legal provisions. One item, a capital increase reserved for members of a company savings plan, was rejected, receiving about 14.8% votes in favor and 85.2% against. Quorum reached 55.840%, with 46,175,805 shares represented, or 45.858% of the share capital.